Sino-Biocan has completed an angel round of funding in the tens of millions of dollars.

Sino-Biocan(Shanghai) Biotech Ltd has completed an angel round of funding in the tens of millions of dollars, with exclusive investment from Sinovation Ventures.

Sino-Biocan (Shanghai) Biotech Ltd is an automated, modularized, closed cell production platform provider in cell & gene therapy field, providing total solution of smart tools innovation and service, devoting to be the industry leader integrating R & D, business development, techinical service, customization and production. 

With the approval of two CAR-T drugs by the U.S. FDA in 2017, cell therapy has become a hot area at the moment. At present, domestic cell drug development funds are gathered and there are many enterprises, the Center for Drug Evaluation(CDE) has accepted 70 IND declarations for cell therapy, and there are more than 200 cell drug enterprises lined up for interviews at the National Institutes for Food and Drug Control  and CDE.

However, the current cell preparation tools are limited by foreign companies such as GE and Miltenyi, resulting in a low local discourse on cell preparation, which also seriously restricts the development of domestic cell therapy companies. Wei Dongbing, the founder of the company, has been the head of Miltenyi China for 8 years and has witnessed the rise and turn of China's cell and gene therapy industry to its booming development, and has deep accumulation and knowledge. We believe that Sino-Biocan will become a star company in the upstream of cell and gene therapy in China and worldwide under the leadership of the founder。